Five Prime Therapeutics, Inc. (NASDAQ:FPRX) is reporting third quarter earnings results on Tuesday 3rd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.6 per share.
For the full year, analysts predict revenues of $ 18.34 million, while looking forward to loss of $ 2.24 per share.
Previous Quarter Performance
Five Prime Therapeutics, Inc. unfold loss for the second quarter of $ 0.48 per share, from the revenue of $ 3.42 million. The quarterly revenues improved 2.70 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.69 per share from $ 4.58 million in revenue. The bottom line results beat street analysts by $ 0.21 or 30.43 percent, at the same time, top line results fell short of analysts by $ 1.16 million or 25.33 percent.
Stock Performance
Shares of Five Prime Therapeutics, Inc. traded up $ 0.08 or 1.75 percent on Monday, reaching $ 4.64 with volume of 154.20 thousand shares. Five Prime Therapeutics, Inc. has traded high as $ 4.72 and has cracked $ 4.52 on the downward trend
The closing price of $ 4.64, representing a 160.57 % increase from the 52 week low of $ 1.75 and a 37.87 % decrease over the 52 week high of $ 7.34.
The company has a market capital of $ 169.95 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 22nd September 2020, upgraded by Guggenheim to Buy from Neutral rating.
Conference Call
Five Prime Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.fiveprime.com
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The companys product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
